Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment-Reference-Cited by-同舟云学术

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment

Published:2018-10-02 Issue: Volume: Page:
ISSN:0964-6906
Container-title:Human Molecular Genetics
language:en
Short-container-title:

Author:

Betts Corinne A¹,McClorey Graham¹,Healicon Richard¹,Hammond Suzan M¹,Manzano Raquel¹,Muses Sofia²,Ball Vicky¹,Godfrey Caroline¹,Merritt Thomas M³,Westering Tirsa¹,O’Donovan Liz⁴,Wells Kim E²,Gait Michael J⁴,Wells Dominic J²,Tyler Damian¹,Wood Matthew J¹

Affiliation:

1. Department of Physiology, Anatomy and Genetics, University of Oxford,South Parks Road, Oxford, UK

2. Department of Comparative Biomedical Sciences, Royal Veterinary College,Royal College Street, London NW1 0TU, UK

3. Clinical Biomanufacturing Facility, Nuffield Department of Clinical Medicine, University of Oxford, Old Road, Oxford, UK

4. Medical Research Council, Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK

Funder

British Heart Foundation

BHF Centre of Research Excellence, Oxford

Medical Research Council

Publisher

Oxford University Press (OUP)

Subject

Genetics(clinical),Genetics,Molecular Biology,General Medicine

Link

http://academic.oup.com/hmg/advance-article-pdf/doi/10.1093/hmg/ddy346/25891680/ddy346.pdf

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies;Pharmaceutics;2023-04-03

2. Cardiac CIP protein regulates dystrophic cardiomyopathy;Molecular Therapy;2022-02

3. Transcriptomic analysis of mdx mouse muscles reveals a signature of early human Duchenne muscular dystrophy;2021-07-16

4. The multifaceted view of heart problem in Duchenne muscular dystrophy;Cellular and Molecular Life Sciences;2021-06-06

5. Delivery of oligonucleotide‐based therapeutics: challenges and opportunities;EMBO Molecular Medicine;2021-04-06